Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-02-24
2010-02-23
O Hara, Eileen B (Department: 1638)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100, C536S023100, C536S024300, C530S350000, C530S387100
Reexamination Certificate
active
07666595
ABSTRACT:
The present invention relates to the identification and use of gene expression profiles with clinical relevance to prostate cancer. In particular, the invention provides the identity of genes whose expression, at the transcriptional and protein levels, is correlated with prostate cancer progression. Methods and kits are described for using these gene expression profiles in the study and/or diagnosis of prostate cancer diseases, in the prediction of prostate cancer progression, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that target these genes or their protein products, in particular for the development of therapeutics for modulating prostate cancer progression.
REFERENCES:
patent: 5972615 (1999-10-01), An et al.
patent: 6171796 (2001-01-01), An et al.
patent: 6703202 (2004-03-01), McGrath et al.
patent: 2002/0192699 (2002-12-01), Zhang et al.
patent: 2003/0113762 (2003-06-01), Warrington
patent: 2003/0134280 (2003-07-01), Munger et al.
patent: 2003/0134324 (2003-07-01), Munger et al.
patent: 2003/0152980 (2003-08-01), Golub et al.
patent: 2003/0215835 (2003-11-01), Sun et al.
patent: 2004/0224306 (2004-11-01), Kuhne et al.
patent: 2006/0063214 (2006-03-01), Alper
patent: 2007/0128639 (2007-06-01), Chinnaiyan et al.
Meng et al., Minichromosome Maintenance Protein 2 Expression in Prostate: Characterization and Association with Outcome after Therapy for Cancer. Clinical Cancer Research, vol. 7, pp. 2712-2718,Sep. 2001.
Baron et al., “Fatty acid synthase: a metabolic oncogene in prostate cancer”,J. Cell Biochem., 2004, 91:47-953.
Bismar et al., “Defining Aggressive Prostate Cancer Using a 12 Gene Model”, Neoplasia, 2006, 8:59-68.
Bracken et al., “EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer”,EMBO J., 2003, 22: 5323-5335.
Brawn et al., “Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates”,Cancer, 1991, 68:1592-1599.
Bubendorf et al., “Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy”,J. Pathol., 1996, 178: 437-441.
Bussemakers et al., “Decreased expression of E-cadherin in the progression of rat prostatic cancer”,Cancer Res., 1992, 52: 2916-2922.
Cheville et al., “Expression of p27kip1 in prostatic adenocarcinoma”,Mod. Pathol., 1998, 11: 324-328.
Cher et al., “Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer”,Genes Chromosomes Cancer, 1994, 11: 153-162.
Choo et al., “Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression”,J. Urol., 2002, 167: 1664-1669.
Cordon-Cardo et al., “Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma”,J. Natl. Cancer Inst., 1998, 90: 1284-1291.
De Marzo et al., “E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens”,Urology, 1999, 53:707-713.
De Marzo et al., “Pathological and molecular aspects of prostate cancer”,Lancet, 2003, 361: 955-964.
Dhanasekaran et al., “Delineation of prognostic biomarkers in prostate cancer”,Nature, 2001, 412: 822-826.
Eisen et al., “Cluster analysis and display of genome-wide expression pattern”,Proc. Natl. Acad. Sci. USA, 1998, 95: 14863-14868.
Epstein et al., “OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate”,Urology, 1995, 45: 81-86.
Etzioni et al., “Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends”,J. Natl. Cancer Inst., 2002, 94: 981-990.
Farhana et aL, “Cyclin B and E2F-1 expression in prostate carcinoma cells treated with the novel retinoid CD437 are regulated by the ubiquitin-mediated pathway”,Cancer Res., 2002, 62: 3842-3849.
Foster et al., “Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome”,Oncogene, 2004, 23: 5871-5879.
Gelmann, “Molecular biology of the androgen receptor”, J. Clin. Oncol., 2002, 20: 3001-3015.
Glinsky et al., “Gene expression profiling predicts clinical outcome of prostate cancer”,J. Clin. Invest., 2004, 113: 913-923.
Golub et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring”,Science, 1999, 286: 531-537.
Guo et al., “Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade”,Clin. Cancer Res., 1997, 3: 2269-2274.
Hale et al., “Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer”,Clin. Cancer Res., 2001, 7: 846-853.
Hofer et al., “The role of metastasis-associated protein 1 in prostate cancer progression”,Cancer Res., 2004, 64: 825-829.
Ihaka and R.R. Gentleman, Journal of Computational and Graphical Statistics, 1996, 5:299-314.
Jiang et al., “Joint analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes”,BMC Bioinformatics, 2004, 5: 81.
Jiang et al., “P504S: a new molecular marker for the detection of prostate carcinoma”,Am. J. Surg. Pathol., 2001, 25: 1397-1404.
Johansson et al., “Natural history of localised prostatic cancer. A population-based study in 223 untreated patients”,Lancet, 1989, I: 799-803.
Kleer et al., “EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells”,Proc. Natl. Acad. Sci. USA, 2003, 100: 11606-11611.
Krajewska et al., “Elevated expression of inhibitor of apoptosis proteins in prostate cancer”,Clinical Cancer Research, 2003, 9: 4914-4925.
Kuefer et al., “alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation”,Am. J. Pathol., 2002, 161: 841-848.
Lapointe J et al., “expression profiling identifies clinically relevant subtypes of prostate cancer”,Proc. Natl. Acad. Sci. USA, 2004, 101: 811-816.
Li and W.H. Wong, “Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection”,Proc. Acad. Sci. USA, 2001, 98: 31-36.
Luo et al., “Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling”,Cancer Res., 2001, 61: 483-4688.
Luo et al., “Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer”,Cancer Res., 2002, 62: 2220-2226.
Luo et al., “Gene expression analysis of prostate cancers”,Mol. Carcinog., 2002, 33: 25-35.
Macoska et al., “Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis”,Genes Chromosomes Cancer, 1993, 8: 88-97.
Macoska et al., “Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer”,Cancer Res., 1994, 54: 3824-3830.
Macoska et al., “Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer”,Cancer Res., 1995, 55: 5390-5395.
Macoska et al., “8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer”,Urology, 2000, 55: 776-782.
Magee et al., “Expression profiling reveals hepsin overexpression in prostate cancer”,Cancer Res., 2001, 61: 5692-5696.
Manley et al., “Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on cl
Demichelis Francesca
Rubin Mark A.
Chen, JD Fangli
Choate Hall & Stewart LLP
Hara Eileen B O
The Brigham and Women's Hospital, Inc.
LandOfFree
Biomarkers for predicting prostate cancer progression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biomarkers for predicting prostate cancer progression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for predicting prostate cancer progression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4162825